The European pharmacovigilance: regulatory aspects

被引:0
|
作者
Dhanani, A [1 ]
Castot, A [1 ]
机构
[1] AFSSAPS, Dept Vigilances, Direct Evaluat Medicaments & Prod Biol, F-93285 St Denis, France
来源
PRESSE MEDICALE | 2000年 / 29卷 / 02期
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Establishment: The European pharmacovigilance system has been operating since 1995 when the European Agency for the Evaluation of Medicinal Products as well as two new European registration procedures were established. Structure: This system is very similar to the French organization and is based on a decentralized collection and validation of safety data by member states and a centralized evaluation and decision making process at the European Agency for the Evaluation of Medicinal Products performed by the Committee for Proprietary Medicinal Products (CPMP) and its Pharmacovigilance Working Party. A European system: In light of the experience gained, the European pharmacovigilance system moved to an interactive system which relies on a close cooperation between member states ensuring the common evaluation and management of safety concerns.
引用
收藏
页码:107 / 110
页数:4
相关论文
共 50 条
  • [41] Compliance in European pharmacovigilance: How compliant is compliant?
    Koster, MC
    Teeuw, B
    Cockburn, I
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2000, 9 (06) : 473 - 478
  • [42] Pharmacovigilance in European clinical trials: Duties of sponsor
    Bertram, D.
    Plattner, V.
    [J]. DRUG SAFETY, 2007, 30 (10) : 936 - 936
  • [43] Impact of Pharmacovigilance and Evaluation Activities-A regulatory Perspective
    Mouchantaf, R.
    Comarova, N.
    Bouterfa, F.
    [J]. DRUG SAFETY, 2017, 40 (10) : 940 - 941
  • [44] A European network of centres for pharmacovigilance and pharmacoepidemiology (ENCePP)
    Wathion, Noel A.
    Blackburn, Stella
    Kurz, Xavier
    Persson, Ingemar R.
    Moride, Yola
    Sturkenboom, Miriam C. J. M.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2008, 17 : S26 - S26
  • [45] Unintended impact of pharmacovigilance regulatory interventions: A systematic review
    Lasys, Tomas
    Santa-Ana-Tellez, Yared
    Siiskonen, Satu J.
    Groenwold, Rolf H. H.
    Gardarsdottir, Helga
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (12) : 3491 - 3502
  • [46] Strategic Partnerships in Pharmacovigilance: Business, Legal, and Regulatory Domains
    Youssef, Ashraf
    Blanchard, Nancy L.
    Hammad, Tarek A.
    [J]. CLINICAL THERAPEUTICS, 2024, 46 (05) : 424 - 428
  • [47] Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
    Sara Francescon
    Giulia Fornasier
    Paolo Baldo
    [J]. Oncology and Therapy, 2016, 4 (2) : 173 - 182
  • [48] Biosimilar Oncology Drugs in Europe: Regulatory and Pharmacovigilance Considerations
    Francescon, Sara
    Fornasier, Giulia
    Baldo, Paolo
    [J]. ONCOLOGY AND THERAPY, 2016, 4 (02) : 173 - 182
  • [49] PRESENT AND FUTURE REGULATORY ASPECTS IN THE EUROPEAN MARKET OF INVITRO DIAGNOSTIC PRODUCTS - THE INDUSTRY POSITION
    SCASSELLATI, GA
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1990, 17 (07): : 699 - 701
  • [50] A comparative analysis of the pharmacovigilance systems of Brazil, Spain, the European Union and the United States based on the information provided by their regulatory agency websites
    Marinho Leal, Marineide
    Madurga Sanz, Mariano
    Castillo Ferrando, Juan Ramon
    Martinez-Martinez, Fernando
    [J]. DARU-JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 27 (01) : 379 - 387